Skip to main content

Torgeir Vaage; CEO

Extensive experience from the financial sector in Norway. For the last ten years been involved in a number of early stage biotechnology companies in the Nordic region in the capacity as CEO and CFO. He holds a MSc from Norges Handelshøyskole (Norway) and a PhD from UC Berkeley.

Prof Aurora Martinez; CTO

PhD in Biochemistry. Professor at Dept. of Biomedicine, University of Bergen. Expertise in biophysics, structural biology, drug design and cellular biology, investigating how structure determines molecular recognition, stability and function in selected biomolecular networks. Expertise in compound screening and early stage drug discovery, with special focus on PKU and development of novel therapies based on pharmacological chaperones.

Dr. Mikael Thomson; Drug Development Consultant

PhD in pharmacology and toxicology), Mikael Thomson has worked in the pharmaceutical area for close to 20 years, and comes with a broad background from drug development, extending from preclinical development through phase 2 clinical work, having worked with both large pharma and biotech start-ups in the Nordic region. He is a member of several pharmaceutical societies and has authored or co-authored more than 50 publications/abstracts related to early drug development as well co-author of several patents.

Dr. Anne-Sophie Schillinger; Project Director

PhD in structural bioinformatics and biophysics. Experience in early stage drug development from academic and industry projects. Extensive experience in business development and project management at the Bergen Technology Transfer Office.

Dr. Oscar Aubi Catevilla; Senior Scientist

PhD in Biochemistry, Dept. Biomedicine, University of Bergen. Experience in compound screening and early stage drug discovery. Deep knowledge of the methodological aspects, technologies and assays in the discovery process of pharmacological chaperones and inhibitors.